796848-80-1

Usage

Uses

Used in Pharmaceutical Industry:
Phenyl 2-chloro-4-hydroxyphenylcarbamate is used as a key intermediate in the synthesis of quinoline-carboxamide compounds, which are important in the development of targeted cancer therapies. One such compound is Lenvatinib (L329400), an orally active inhibitor of multiple receptor tyrosine kinases, including VEGF, FGF, and SCF receptors. This makes phenyl 2-chloro-4-hydroxyphenylcarbamate essential for the production of innovative cancer treatments that can effectively target and inhibit the growth of tumor cells.

Upstream product

• 1885-14-9 phenyl chloroformate 
• 17609-80-2 4-amino-3-chlorophenol 

Downstream Products

• 796848-79-8 1-(2-chloro-4-hydroxyphenyl)-3-cyclopropyl urea 
• 417716-92-8 lenvatinib 

Relevant academic research and scientific papers

PROCESS FOR THE PREPARATION OF LENVATINIB

The present invention relates to a process for the preparation of Lenvatinib of formula (I) from 4-amino-3-chloro-phenol and 4-chloro-7-methoxyquinoline-6-carboxamide.

Method for refining Lenvatinib mesylate

The invention discloses a method for refining Lenvatinib mesylate. The method for refining the Lenvatinib mesylate, provided by the invention, comprises the following step: subjecting a solution formed by an organic solvent and crude Lenvatinib mesylate t

Isotope enrichment lenvatinib

The invention discloses isotope enrichment lenvatinib, a pharmaceutically acceptable salt form thereof, and a treatment method using the isotope enrichment lenvatinib, and specifically relates to an isotope enrichment compound represented by a formula I o

Synthesis and in vitro evaluation of piperazinyl-ureido sulfamates as steroid sulfatase inhibitors

Two new piperazinyl-ureido single ring aryl sulfamate-based inhibitor series were designed against the emerging oncology drug target steroid sulfatase (STS), for which there are existing potent steroidal and non-steroidal agents in clinical trials. 4-(Pip

Substituted urea compound and pharmaceutically acceptable salts or solvates thereof, application for substituted urea compound and pharmaceutically acceptable salts or solvates of substituted urea compound, and pharmaceuticals and pharmaceutical compositi

The invention provides a substituted urea compound, and pharmaceutically acceptable salts or solvates thereof. The invention also provides an application of the substituted urea compound, the pharmaceutically acceptable salts or the solvates of the substi

Deuterated compound, salt, preparation method, drug composition and application thereof

The invention discloses a compound with the structure shown in the formula (I) and pharmacologically acceptable salt. The invention further provides a preparation method of the compound shown in the formula (I) and a drug composition containing the compou

Preparation method of lenvatinib

The invention belongs to the field of medical chemistry, and provides a preparation method of a compound of lenvatinib. The method is characterized by comprising the following steps that (1) under the existence of an organic solvent and an alkali reagent,

Amorphous salt of 4-(3-chiloro-4-(cycloproplylaminocarbonyl)aminophenoxy)-7-method-6-quinolinecarboxamide and process for preparing the same

An amorphous form of a salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide.

Polymorph of 4-[3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy]-7-methoxy-6- quinolinecarboxamide and a process for the preparation of the same

A polymorph (A) of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide, having a diffraction peak at a diffraction angle (2θ±0.2°) of 15.75° in a powder X-ray diffraction; and a polymorph (B) of 4-[3-chloro-4-(cyclopropy

MEDICINAL COMPOSITION

A pharmaceutical composition comprising: an active ingredient consisting of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide, salt thereof, or solvate of the foregoing; and (i) a compound, a 5% (w/w) aqueous solution